SynthesisWorld journal of surgical oncology2023
Does adjuvant hepatic artery infusion chemotherapy improve patient outcomes for hepatocellular carcinoma following liver resection? A meta-analysis.
Synthesis in World journal of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Can adjuvant immune checkpoint inhibitors improve the long-term outcomes of hepatocellular carcinoma with high-risk recurrent factors after liver resection? A meta-analysis and systematic review.Frontiers in oncology · 2024Pooled it
- Evidence summary of nursing care of arterial drug administration and catheter management for HAIC in hepatocellular carcinoma.Medicine · 2026Article
- Anti-angiogenic therapy combined with immune checkpoint blockade mediates CCR7 + CD8 + T-cell entry into HCC through high endothelial venules.Hepatology (Baltimore, Md.) · 2026Article
- Prognostic Significance of Combined α-Fetoprotein and PIVKA-II for Hepatocellular Carcinoma After Hepatectomy.Journal of hepatocellular carcinoma · 2026Article
- Current Advances in Classification, Prediction and Management of Microvascular Invasion in Hepatocellular Carcinoma.Journal of cellular and molecular medicine · 2025Review
- Adjuvant HAIC combined with anlotinib and TQB2450 for resected high-risk hepatocellular carcinoma.Innovation (Cambridge (Mass.)) · 2025Article
- Chinese expert consensus on the diagnosis and treatment of hepatocellular carcinoma with microvascular invasion (2024 edition).Hepatobiliary surgery and nutrition · 2025Review
- Adjuvant Hepatic Arterial Infusion Chemotherapy Versus Transarterial Chemoembolization for Preventing Early Recurrence After Surgical Resection in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Comparative efficacy of postoperative adjuvant transcatheter arterial chemoembolization and hepatic artery infusion chemotherapy in patients with BCLC stage 0-B hepatocellular carcinoma at high risk of recurrence following radical resection.Frontiers in pharmacology · 2025Article
- Efficacy of postoperative adjuvant hepatic artery infusion chemotherapy for hepatocellular carcinoma in microvascular invasion: a propensity-matched score.Frontiers in surgery · 2025Article
- Adjuvant camrelizumab plus apatinib in resected hepatocellular carcinoma with microvascular invasion: a multi-center real world study.Hepatobiliary surgery and nutrition · 2024Article
- Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant hepatic artery infusion chemotherapy (HAIC) has been shown to be beneficial to the patient outcomes in hepatocellular carcinoma (HCC).
methodsRandomized controlled trials (RCTs) and non-RCTs were identified from six databases up to January 26, 2023. Patient outcomes were assessed using overall survival (OS) and disease-free survival (DFS). Data were presented as hazard ratios (HR, 95% confidence intervals, or CIs).
resultsThe present systematic review included 2 RCTs and 9 non-RCTs with a total of 1290 cases. Adjuvant HAIC improved OS (HR of 0.69; 95% CI of 0.56-0.84; p < 0.01) and DFS (HR of 0.64; 95% CI of 0.49-0.83; p < 0.01). Subgroup analysis showed that HCC patients with portal vein invasion (PVI) or microvascular invasion (MVI) benefit from adjuvant HAIC in terms of OS ((HR of 0.43; 95% CI of 0.19-0.95; p < 0.01) and (HR of 0.43; 95% CI of 0.19-0.95; p = 0.0373), respectively) and DFS ((HR of 0.38; 95% CI of 0.21-0.69; p < 0.01) and (HR of 0.73; 95% CI of 0.60-0.88; p = 0.0125), respectively). Adjuvant HAIC with the oxaliplatin-based approach significantly improved OS (HR of 0.60; 95% CI of 0.36-0.84; p = 0.02) and (HR of 0.59; 95% CI of 0.43-0.75; p < 0.01), respectively).
conclusionThis meta-analysis demonstrated that postoperative adjuvant HAIC was beneficial in HCC patients with PVI and MVI. It remains unclear whether HAIC can improve the survival outcome in all HCC patients after hepatic resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.